Salidroside

Salidroside (2-(4-hydroxyphenyl)ethyl beta-D-glucopyranoside; CAS 10338-51-9) is the principal bioactive glycoside of the adaptogenic plant Rhodiola rosea L. and related Rhodiola species of the family Crassulaceae. It is the 8-O-beta-D-glucoside of tyrosol (4-hydroxyphenylethanol), a simple phenylethanol aglycone that is also the primary circulating metabolite of salidroside following oral administration. The compound has been used in traditional Tibetan, Chinese, and Scandinavian medicine for centuries as a general tonic and adaptogen, and modern pharmacological investigation has identified a remarkably diverse spectrum of biological activities centered on three principal molecular mechanisms: activation of the AMP-activated protein kinase (AMPK) signaling cascade with downstream engagement of the PI3K/Akt/GSK3beta and SIRT1 pathways; activation of the nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) antioxidant response axis; and suppression of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) pro-inflammatory transcriptional program with consequent reduction of tumor necrosis factor alpha, interleukin-1 beta, interleukin-6, and NLRP3 inflammasome activation.

Preclinical pharmacology studies conducted across multiple organ systems have demonstrated neuroprotective efficacy in models of cerebral ischemia/reperfusion injury, Alzheimer's disease (amyloid beta-induced neurotoxicity and ferroptosis), Parkinson's disease (MPTP and 6-OHDA models), traumatic brain injury, and depression; cardioprotective activity against ischemia/reperfusion injury, doxorubicin-induced cardiotoxicity, and atherosclerosis; hepatoprotective effects against carbon tetrachloride and high-fat-diet-induced liver injury and nonalcoholic steatohepatitis; antidiabetic activity through amelioration of insulin resistance via the mitochondria-associated AMPK/PI3K/Akt/GSK3beta pathway; renoprotective effects in diabetic nephropathy; and anti-tumor activity in breast, lung, colorectal, and gastric cancer models through inhibition of proliferation, migration, and invasion via the AKT and MEK/ERK signaling pathways.

Pharmacokinetics in rodents are characterized by rapid oral absorption (Tmax approximately 0.5 to 1 hour), moderate oral bioavailability (approximately 20 to 32 percent in rats), extensive first-pass metabolism to the aglycone p-tyrosol by intestinal and hepatic beta-glucosidases, wide tissue distribution with preferential accumulation in kidney, liver, and heart, and renal elimination of conjugated metabolites. The compound crosses the blood-brain barrier. Salidroside demonstrates a favorable safety profile: the acute oral LD50 in rats exceeds 5000 mg/kg body weight, and subchronic toxicity studies at doses up to 100 mg/kg/day have not produced organ toxicity, genotoxicity, or teratogenicity at the studied doses.

Human clinical evidence remains limited relative to the preclinical literature. Rhodiola rosea standardized extracts containing salidroside (typically standardized to 1 to 3 percent salidroside) have demonstrated efficacy in randomized controlled trials for stress-related fatigue, mild to moderate depression, generalized anxiety, and cognitive function under stress conditions. A 2024 exploratory randomized double-blind placebo-controlled trial of pure biosynthetic salidroside at 60 mg/day for 16 days in healthy active young adults demonstrated enhanced oxygen utilization during high-intensity intermittent exercise, stable mood states, and mitigated exercise-induced muscle damage. A randomized controlled trial of 60 breast cancer patients reported no clinical adverse events during salidroside administration as adjunctive therapy.

This monograph reviews the chemistry, natural and synthetic sources, and structural pharmacology of salidroside; the multi-target molecular mechanisms across the AMPK, Nrf2, and NF-kappaB axes; the comprehensive preclinical pharmacology across neurological, cardiovascular, metabolic, hepatic, renal, and oncological models; the available human pharmacokinetic and clinical evidence; sourcing, quality verification, and standardization considerations; reconstitution and handling protocols; stack-interaction implications; adverse-event and safety signal characterization; and a structured comparative assessment of five adaptogenic or neuroprotective compounds against salidroside on five competency standards.